semaglutide and intestinal obstruction Ozempic Blockage Lawsuits A potentially serious adverse effect

Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved

The face often shows it first rapid fat loss can leave the cheeks and temples looking hollow or deflated, a change some people describe as looking older or more drawn after losing weight

T.BamburgJ

The Liberty team is so supportive through my weight loss journey